A Randomized Comparative Study Of Efficacy And Safety Of Epalrestat And Methylcobalamin In Patients With Diabetic Neuropathy

Dr. C. Preeth; Prof. P.Jacob Verghese; Dr. J.Nandhakumar

Volume : X, Issue : I, January - 2020

A Randomized Comparative Study Of Efficacy And Safety Of Epalrestat And Methylcobalamin In Patients With Diabetic Neuropathy

Dr. C. Preeth, Prof. P. Jacob Verghese, Dr. J. Nandhakumar

Abstract :

Intorduction Diabetic neuropathy is a common complication in nearly 50% of over all diabetes population. Recently Epalrestat and Methylcobalamin are widely used in clinical practice to manage diabetic neuropathy. This study was aimed to compare the efficacy and safety of Epalrestat and Methylcobalamin in patients with diabetic neuropathy. Methods: A total number of 110 patients with diabetic neuropathy were divided into two groups; group A administered with 150 mg of Epalrestat and group B administered with 1500 mcg of Methylcobalamin once daily basis. The treatment period was 12 weeks with monitoring on week 4, 8 & 12 of the study. At base line and at follow up visits parameters like pain intensity by VAS pain score, loss of sensation, burning sensation, numbness, muscle cramps, spontaneous pain, weakness, dizziness, loss of sensation of heat & cold assessed by MNSI & HbA1C. Results: A significant improvement in all the efficacy parameters was observed with Epalrestat treatment compared to methylcobalamin treatment. Epalrestat treatment is associated with very few adverse events. Patients as well as physicians reported that the Epalrestat treatment is better–quality in efficacy and safety parameters compared to Methylcobalamin. Conclusion: The present study concludes that Epalrestat has superior efficacy and safety profile than Methylcobalamin in the treatment of diabetic neuropathy.